{"nctId":"NCT00236899","briefTitle":"Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC","startDateStruct":{"date":"2005-09"},"conditions":["Metastatic Breast Cancer (MBC)"],"count":241,"armGroups":[{"label":"A: Docetaxel and Gemcitabine (Tri-weekly)","type":"EXPERIMENTAL","interventionNames":["Drug: Gemcitabine","Drug: Docetaxel"]},{"label":"B: Paclitaxel and Gemcitabine (Tri-weekly)","type":"EXPERIMENTAL","interventionNames":["Drug: Gemcitabine","Drug: Paclitaxel"]},{"label":"C: Docetaxel and Gemcitabine (Weekly)","type":"EXPERIMENTAL","interventionNames":["Drug: Gemcitabine","Drug: Docetaxel"]},{"label":"D: Paclitaxel and Gemcitabine (Weekly)","type":"EXPERIMENTAL","interventionNames":["Drug: Gemcitabine","Drug: Paclitaxel"]}],"interventions":[{"name":"Gemcitabine","otherNames":["LY188011","Gemzar"]},{"name":"Docetaxel","otherNames":[]},{"name":"Paclitaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologic diagnosis of metastatic breast cancer (MBC).\n* Prior neoadjuvant or adjuvant taxanes regimen is allowed if ≥12 months since completion of the regimen.\n* Relapsing after receiving one adjuvant/neoadjuvant chemotherapy containing an anthracycline if not clinically contraindicated.\n* Patients with measurable disease.\n* Previous hormonal therapy for adjuvant setting or metastatic disease.\n\nExclusion Criteria:\n\n* Previous chemotherapy for MBC\n* Previous chemotherapy with gemcitabine in any setting of disease\n* Patient candidable to treatment with trastuzumab.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Progressive Disease (TTPD) by Treatment Schedule","description":"TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":null},{"groupId":"OG001","value":"7.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) by Treatment Schedule","description":"OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.11","spread":null},{"groupId":"OG001","value":"20.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) by Treatment Drug","description":"OS is the duration from enrollment to time of death as a result of any cause. For participants who are alive, OS is censored at the last contact (date of the last follow-up visit).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.11","spread":null},{"groupId":"OG001","value":"23.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) by Treatment Schedule","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.43","spread":null},{"groupId":"OG001","value":"33.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.84","spread":null},{"groupId":"OG001","value":"5.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.59","spread":null},{"groupId":"OG001","value":"27.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.93","spread":null},{"groupId":"OG001","value":"40.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.37","spread":null},{"groupId":"OG001","value":"12.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null},{"groupId":"OG001","value":"1.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":null},{"groupId":"OG001","value":"12.10","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Progressive Disease (TTPD) by Treatment Drug","description":"TTPD is defined as the time from the day of treatment to first observation of documented disease progression or death due to any cause, whichever comes first. TTPD was censored at the time of last follow-up for patients who were still alive without progression. Tumor response was assessed in cancer patients by using Response Evaluation Criteria in Solid Tumors (RECIST), which define when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatments. Progressive Disease is a ≥20% increase in sum of longest diameter of target lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.74","spread":null},{"groupId":"OG001","value":"7.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate(ORR) by Treatment Drug","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response≥30% decrease in sum of longest diameter of target lesions; Progressive Disease≥20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Not Available=participants assessed whose data were not available. Not Assessed=participants who did not participate in assessments. The ORR=sum of complete and partial tumor responses observed, divided by the total number of evaluable participants.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"39.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.08","spread":null},{"groupId":"OG001","value":"7.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.14","spread":null},{"groupId":"OG001","value":"32.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.20","spread":null},{"groupId":"OG001","value":"32.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.80","spread":null},{"groupId":"OG001","value":"16.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null},{"groupId":"OG001","value":"1.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.93","spread":null},{"groupId":"OG001","value":"9.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious and Nonserious Adverse Events (AEs)","description":"Summary tables of serious adverse events (SAEs) and all other nonserious AEs are located in the Reported Adverse Event Module.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at Beginning of 3-Week or 4-Week Cycle","description":"RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL by treatment arm are provided. Arms A (Docetaxel and Gemcitabine 3 Weekly) and B (Paclitaxel and Gemcitabine 3 Weekly) were assessed every 3 weeks. Arms C (Docetaxel and Gemcitabine Weekly) and D (Paclitaxel and Gemcitabine Weekly) were assessed every 4 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life (QOL) Using the Rotterdam Symptom Scale Checklist (RSSC) at 30-Day Post-therapy Visit","description":"RSSC is a valid and reliable measure of psychological and physical distress of cancer patients. Overall QOL is assessed on a 7-point scale (1=Excellent to 7=Extremely Poor). Categories include Excellent, Good, Moderately Good, Neither Good nor Bad, Rather Poor, Poor, and Extremely Poor. Number of responses to the overall QOL (using the 7-point scale) by treatment arm are provided.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"47","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":59},"commonTop":["Neutropenia","Nausea","Pyrexia","Alopecia","Asthenia"]}}}